NAFLD is a leading cause of chronic liver disease and has doubled within the last decade.
SNP Therapeutics has developed a genetic test and a medical nutrition treatment approach for individuals with NAFLD that may reduce the risk of disease progression for a significant subset of individuals. The genetic test has a high level of accuracy in predicting if individuals, who have a specific set of genetic polymorphism or variants, will develop NAFLD who are not managing their diet and weight effectively.
Additionally, There is a significant subset of the NAFLD population that can be identified and treated to prevent and reverse this potentially progressive disease with medical nutrition and lifestyle changes.
It is estimated that up to ¼ of the world population and 1/3 of the US and European populations may have some level of this progressive metabolic liver condition. Most of this prevalence is undiagnosed and unlikely to result in progressive loss of liver function. However, the level of risk for disease progression for the estimate 290 million people worldwide with NAFLD is not insignificant. Studies suggest that about 25% of NAFLD patients will get steatohepatitis with a high risk of fibrosis and cirrhosis.
There is considerable unmet need in diagnosis and treatment for NAFLD. There are currently no FDA approved treatments for NAFLD or NASH. There are a number of investigational drug candidates in various stages of development.